BETHESDA, Md.--(BUSINESS WIRE)--
India Globalization Capital, Inc. (IGC) announces that it will host educational conferences in two of the largest cities in Puerto Rico on April 27, 2019 (San Juan) and April 28, 2019 (Ponce) from 9:00 a.m. to 5:00 p.m. each day. These full-day events will feature presentations for physicians in the morning and provide programs tailored to technicians, patients, and caregivers in the afternoon. These events are part of a series of educational initiatives IGC is hosting in support of Hyalolex™, the Company’s cannabinoid-based product designed to help improve the lives of patients suffering from Alzheimer’s disease, as well as improve the lives of caregivers.
The Company previously hosted an educational conference on Saturday, March 30, 2019, in San Juan. This full-day event was similarly organized as a forum for distinguished speakers, including cannabis educators and a quality of life specialist, to address managing Alzheimer’s disease with Cannabinoids. The conference featured a variety of informative presentations and workshops and was attended by an estimated 200 individuals, including physicians, industry insiders, patients, and their caregivers.
By hosting these conferences, the Company obtains direct feedback from physicians, patients, caregivers, and the owners of dispensaries. According to data from alz.org, there are approximately 5.8 million individuals in the U.S. with Alzheimer’s dementia in 2019 with a projected cost to the U.S. health care system of $290 billion. Estimates suggest that the cost by 2050 will approach $1.1 trillion in 2019 dollars. There is no cure for Alzheimer’s disease.
The IGC formulation delivers micro doses of cannabinoids with the goal of helping to manage Alzheimer’s -related symptoms such as anxiety, aggression, and sleep disorder, and it is intended to provide improvement in the quality of life for patients. One particular aspect that we hope to address is that of caregiver distress. The Company proposes to conduct clinical trials as part of its strategy to develop pharmaceutical products.
“The launch of Hyalolex™ in a smaller controlled environment like Puerto Rico allows us to develop and refine a market penetration strategy and financial model for the product that can then be scaled to other parts of the country that possess significantly larger addressable Alzheimer’s populations,” stated Ram Mukunda, CEO
As previously reported, the current MSRP for a 30 ml bottle of Hyalolex™ is $55.00. For more information about Hyalolex™, visit www.hyalolex.com.
IGC has two lines of business: infrastructure and hemp/cannabinoid derived products. The company is based in Maryland, U.S.A. Our website: www.igcinc.us.Twitter @IGCIR
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on IGC’s expectations and are subject to a number of risks and uncertainties, certain of which are beyond IGC’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, competitive conditions in the industries in which IGC operates, failure to commercialize one or more of the technologies of IGC, general economic conditions that are less favorable than expected, and other factors, many of which are discussed in our SEC filings. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will in fact occur.